Table 1.
Cytotoxic, Anti-inflammatory, and Antioxidant Activities of Tested Compounds.
| Cytotoxicity (anti cell proliferation activity) in a panel of cell lines | Inhibition of NF-κ B activity in SW1353 cells | Antioxidant Activity (inhibition of ROS generation) in HL-60 cells | Inhibition of iNOS activity (NO production) in RAW 264.7 cells | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| IC50 (μg/mL) | IC50 (μg/mL) | IC50 (μg/mL) | IC50 (μg/mL) | |||||||||
| Compound | SK- MEL1 | KB1 | BT- 5491 | SK- OV-31 | VERO2 | LLC-PK112 | NF-κB | SP-1 | Antioxidant activity | Cytotoxicity | iNOS | Cytotoxicity |
| 1 (arachidin-1) | 15.0 | 4.8 | 4.8 | 14.5 | 12.0 | 2.8 | 12.0 | - | 0.45 | 5.2 | 1.9 | 8.3 |
| 2 (arachidin-2) | 20.0 | 22.5 | 7.5 | - | 13.5 | 13.5 | 0.025 | <0.025 | 0.04 | 16.0 | 4.1 | - |
| 3 (arachidin-3) | - | - | - | - | - | - | 18.0 | - | 0.17 | - | 6.0 | - |
| 4 (SB-1) | - | - | - | - | - | - | - | - | 0.3 | - | >25 | - |
| 5 (chiricanine A) | 20.0 | - | - | - | - | 19.5 | - | - | - | 19.0 | 6.5 | 13.0 |
| 6 (arahypin-1) | >25 | - | - | - | - | - | - | - | 0.35 | >31.3 | - | - |
| 7 (arahypin-2) | >25 | - | - | - | - | - | - | - | 0.19 | - | - | - |
| 8 (arahypin-3) | - | - | - | - | - | - | - | - | 0.4 | - | - | - |
| 9 (arahypin-4) | - | - | - | - | - | - | - | >25 | 9.5 | >31.3 | - | - |
| 10 (arahypin-5) | 17.5 | >25 | >25 | - | >25 | 19.5 | - | - | 1.3 | 4.5 | 7.0 | 16.0 |
| 11 | 12.5 | 13.8 | 13.0 | 17.0 | 13.0 | 10.5 | 14.5 | 12.5 | - | 18.0 | 6.9 | 10.5 |
| 12 | - | - | - | - | - | - | - | - | 20.0 | >25 | - | - |
| 13 | - | - | - | - | - | - | 19.5 | 25.0 | - | 4.0 | 8.0 | 19.5 |
| 14 | - | - | - | - | - | - | >25 | >25 | - | 19.0 | 11.4 | 22.0 |
| 15 | - | - | - | - | 19.5 | 12.0 | - | - | - | 4.0 | 10.3 | - |
| 16 | - | - | - | - | - | >25 | - | - | 0.012 | 17.0 | 19.5 | - |
| 17 | - | - | - | - | - | - | - | - | 0.027 | 9.0 | 20.0 | - |
| 18 | - | - | - | - | - | - | - | - | - | >25 | >25 | - |
| 19 | - | - | - | - | - | - | 17.0 | 23.0 | - | 18.0 | 8.5 | 12.0 |
| 21 (pterostilbene) | - | - | - | - | - | - | - | - | 0.3 | 21.0 | 9.9 | - |
| 22 | - | >25 | 20.0 | >25 | 15.5 | 14.5 | 22.5 | - | 0.8 | 25.0 | 4.8 | 9.0 |
| 23 | - | - | - | - | - | - | - | - | 0.55 | 20.0 | - | - |
| 24 (resveratrol) | - | - | - | - | - | >25 | 18.5 | >25 | 0.28 | 8.0 | 10.0 | - |
| Doxorubicin3 | 0.8 | 1.45 | 1.35 | 1.3 | >5 | 0.9 | 0.24 | |||||
| Parthenolide3 | 0.8 | 8.35 | 0.42 | 13.5 | ||||||||
| Trolox3 | 0.11 | |||||||||||
1
Cancer cells.
2
Noncancer cells. SK-MEL – Human malignant melanoma; KB – Human oral epidermal carcinoma; BT-549 – Human breast ductal carcinoma; SK-OV-3 – Human ovary carcinoma; Vero – Monkey kidney fibroblasts; LLC-PK11 – Pig kidney epithelial cells.
3
Standard compounds with known biological activities. Hyphen (-) means no activity up to 25 μg/mL.